{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T08:40:06Z","timestamp":1740818406486,"version":"3.38.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2010,12,31]],"date-time":"2010-12-31T00:00:00Z","timestamp":1293753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s12032-010-9654-5","type":"journal-article","created":{"date-parts":[[2010,12,30]],"date-time":"2010-12-30T16:49:09Z","timestamp":1293727749000},"page":"2-7","source":"Crossref","is-referenced-by-count":2,"title":["Gemcitabine and cisplatin salvage regimen in heavily pretreated metastatic breast cancer: a Brazilian experience"],"prefix":"10.1007","volume":"28","author":[{"given":"Luiz Henrique","family":"de Lima Ara\u00fajo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos Veloso","family":"Moitinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria Fantini","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cleudes Alice Sousa","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9lio","family":"Noronha J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,31]]},"reference":[{"issue":"4","key":"9654_CR1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin. 2009;59(4):225\u201349.","journal-title":"CA Cancer J Clin"},{"key":"9654_CR2","unstructured":"Instituto Nacional de C\u00e2ncer\/Minist\u00e9rio da Sa\u00fade. Estimativa 2010: incid\u00eancia de c\u00e2ncer no Brasil. Rio de Janeiro: INCA. [Last access in 05\/04\/2010]. Available at: http:\/\/www.inca.gov.br ."},{"key":"9654_CR3","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1200\/JCO.2000.18.11.2245","volume":"18","author":"RA Nagourney","year":"2000","unstructured":"Nagourney RA, Link JS, Blitzer JB, et al. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol. 2000;18:2245\u20139.","journal-title":"J Clin Oncol"},{"key":"9654_CR4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s00280-005-0093-5","volume":"57","author":"V Heinemann","year":"2006","unstructured":"Heinemann V, Stemmler HJ, Wohlrab A, et al. High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2006;57:640\u20136.","journal-title":"Cancer Chemother Pharmacol"},{"key":"9654_CR5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00280-006-0266-x","volume":"59","author":"JH Seo","year":"2007","unstructured":"Seo JH, Oh SC, Choi CW, et al. Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. Cancer Chemother Pharmacol. 2007;59:269\u201374.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"9654_CR6","first-page":"8","volume":"16","author":"TZM Mohran","year":"2004","unstructured":"Mohran TZM. Gemcitabine and cisplatin combination chemotherapy as a first-line treatment in patients with metastatic breast cancer. J Egypt Natl Cancer Inst. 2004;16(1):8\u201314.","journal-title":"J Egypt Natl Cancer Inst"},{"issue":"2","key":"9654_CR7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.coc.0000144815.54746.d0","volume":"28","author":"PA Burch","year":"2005","unstructured":"Burch PA, Mailliard JA, Hillman DW, et al. Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial. Am J Clin Oncol. 2005;28(2):195\u2013200.","journal-title":"Am J Clin Oncol"},{"issue":"13","key":"9654_CR8","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1200\/JCO.2008.17.4839","volume":"27","author":"HK Chew","year":"2009","unstructured":"Chew HK, Doroshow JH, Frankel P, et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol. 2009;27(13):2163\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"9654_CR9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI. 2000;92(3):205\u201316.","journal-title":"JNCI"},{"key":"9654_CR10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"9654_CR11","volume-title":"Statistical models and methods for life-time data","author":"JS Lawless","year":"1982","unstructured":"Lawless JS. Statistical models and methods for life-time data. New York: Wiley; 1982."},{"key":"9654_CR12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187\u2013220.","journal-title":"J R Stat Soc"},{"key":"9654_CR13","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1200\/JCO.2004.08.176","volume":"22","author":"TD Shanafelt","year":"2004","unstructured":"Shanafelt TD, Loprinzi C, Marks R, et al. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol. 2004;22:1966\u201374.","journal-title":"J Clin Oncol"},{"issue":"4","key":"9654_CR14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00432-009-0687-0","volume":"136","author":"HR Kim","year":"2010","unstructured":"Kim HR, Kang MS, Na II, et al. The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients. J Cancer Res Clin Oncol. 2010;136(4):547\u201352.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"9654_CR15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1897-4287-7-8","volume":"7","author":"EN Imyanitov","year":"2009","unstructured":"Imyanitov EN. Breast cancer therapy for BRCA1 carriers: moving towards platinum standard? Hered Cancer Clin Pract. 2009;7(1):8\u201310.","journal-title":"Hered Cancer Clin Pract"},{"key":"9654_CR16","doi-asserted-by":"crossref","unstructured":"Byrski T, Foszczynska-Kloda M, Huzarski T, et al. Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC). J Clin Oncol 2009;27:15s (suppl; abstr 1099).","DOI":"10.1200\/jco.2009.27.15_suppl.1099"},{"issue":"8","key":"9654_CR17","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/cncr.23837","volume":"113","author":"J Bines","year":"2008","unstructured":"Bines J, Eniu A. Effective but cost-prohibitive drugs in breast cancer treatment. A clinician\u2019s perspective. Cancer. 2008;113(8):2353\u20138.","journal-title":"Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9654-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-010-9654-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9654-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T07:29:34Z","timestamp":1740814174000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-010-9654-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,31]]},"references-count":17,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9654"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9654-5","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"type":"print","value":"1357-0560"},{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2010,12,31]]}}}